Breakthrough in Tumor Vaccine Development Pain Points: A High-Efficiency Preclinical Immunogenicity and Efficacy Evaluation Platform

Core Value: Address the industry bottlenecks of difficult immunogenicity assessment and low clinical translation rate for tumor vaccines, and accelerate the screening of vaccine candidates through customized models and a multi-dimensional detection system.

1、Service Overview

Positioning & Pain Points:

Tumor vaccine development is confronted with challenges such as inaccurate immune response assessment and the lack of human relevance in preclinical models. Traditional animal models fail to simulate the human immune microenvironment, leading to significant deviations in efficacy prediction and prolonged R&D cycles.

Solutions:

Leveraging our professional tumor vaccine development platform, we integrate humanized immune models, multi-omics immune monitoring and a GLP-aligned standard system to deliver one-stop evaluation services spanning from antigen design to in vivo efficacy assessment, significantly reducing the risk of clinical trial failure.

2、Our Services

Immunogenicity Assessment

• T Cell Response Detection:
  • ELISPOT (Detection of IFN-γ, IL-2 and other cytokines)
  • Flow Cytometry (Antigen-specific T cell expansion, memory T cell phenotypic analysis)
  • Applicable Scenarios: Verification of immune activation efficacy for DNA/mRNA vaccines and dendritic cell vaccines.

In Vivo Efficacy Validation

• Humanized Tumor Models:
  • CDX/PDX Models: Human tumor tissue engraftment for evaluating tumor growth inhibition efficacy of vaccines (tumor weight/volume changes, survival prolongation).
  • Immune Reconstitution Models: Human PBMC engraftment in immunodeficient mice for simulating the human immune microenvironment.
  • Humanized Target Tumor Models (IO-Permissive Mouse Models): Humanized target modification of mouse tumor cells for evaluating tumor vaccine efficacy in immunocompetent mice.
• Combination Therapy Evaluation: Efficacy testing of vaccine combined with immune checkpoint inhibitors (e.g., PD-1).

In-Depth Analysis of Immune Mechanisms

• Immune Cell Infiltration: Detection of immune cell infiltration in tumor tissues via multiplex immunohistochemistry (IHC).
• Inflammatory Cytokines in the Tumor Microenvironment: Multiplex cytokine detection of inflammatory cytokines in serum/tumor microenvironment (e.g., TNF-α, IL-6).

3、Technology Platforms and Advantages

Technical Platforms

• ELISPOT High-Throughput Platform.
  • Sensitivity reaches the single-cell level, enabling detection of 1 in 1 million positive cells.
  • Supports simultaneous analysis of multi-cytokine detection (e.g., IFN-γ/IL-2/TNF-α/IL-4, etc.).
• Flow Cytometry Analysis Platform:
  • Develops multi-color panel protocols for precise analysis of T cell subset differentiation.

Differentiated Advantages

• Model Innovation:

Offers a platform combining PDX models with immune-reconstituted models, highly simulating the clinical immune microenvironment.

• Data Dimensions:

Integrates immune response + tumor suppression + survival data to provide multi-dimensional pharmacodynamic reports.

4、Service Process

• Requirements Communication (24-hour Response):

Customize experimental protocols (antigen type, model selection, indicators detection).

• Model Construction & Drug Administration:

Provide tumor cell line/PDX model implantation;vaccine immunization cycle: 2–4 weeks.

• Real-time Data Sharing:

Access raw ELISPOT/flow cytometry/imaging data via a dedicated client portal.

• Report Delivery:

Include statistical analysis, raw images, and GLP-aligned standard reports.

5、Quality Control

• Operational Specifications:

The entire experiment follows GLP-aligned standards with the execution of over 200 SOPs.

• Data Traceability:

An Electronic Lab Notebook (ELN) system ensures complete and traceable data.

6、Case Studies

• Case 1: Evaluation of Therapeutic HPV Vaccine
  • Model: TC-1 Cervical Cancer CDX Model (C57BL/6 Mice)
  • Results:
  • ELISPOT assay showed a 5-fold increase in antigen-specific IFN-γ+ spot count (vs. control group).
  • Tumor weight inhibition rate: 68%.
• More Cases: Click to view the Tumor Immunotherapy Case Library

7、Collaboration Advantages

• Full-Cycle Support: Covers antigen design → immunogenicity → in vivo pharmacodynamics → mechanism research.
• Efficient Delivery: Standard experimental cycle is 30% faster than the industry average (ELISPOT results available in 7 days).
• Cost Optimization: Shared model library reduces PDX model reuse costs by 50%.

8、FAQ

• Q1:Do you support personalized neoantigen vaccine testing?

Yes. PDX models can be constructed based on patient tumor samples, or immunogenicity screening of mutant peptide libraries can be provided.

• Q2: Can the synergistic effect between vaccines and immunotherapies be evaluated?

Customizable combination therapy protocols (e.g., vaccine + PD-1/CTLA-4 inhibitors) are available, with data on tumor inhibition rate, immune cell activation, etc..

• Q3: Does the data delivery meet international regulatory filing requirements?

Yes, we can provide GLP-aligned standard reports, and also support supplementary data for FDA/EMA/NMPA regulatory filings.

9、Laboratory Highlights

• View the Full Laboratory Panorama

View More

10、Contact Us

• Phone: +86 188 0203 5152 (24h Response)
• Email: 3691125803@qq.com
• Online Form: Get a Free Proposal
• Resource Downloads:
  • Technical White Paper for Tumor Vaccine Development Platform
  • Immunotherapy Case Collection (including raw data)
• Submit your requirements and receive a customized plan within 24 hours → Consult Now